Autoimmune Diseases
Welcome,         Profile    Billing    Logout  
 293 Companies   490 Products   490 Products   199 Mechanisms of Action   25 Trials   7787 News 


«12...8788899091929394959697...156157»
  • ||||||||||  Tysabri (natalizumab) / Biogen, Royalty
    Trial completion, Enrollment change, Trial primary completion date:  Pregnancy Exposure Registry for Tysabri® (clinicaltrials.gov) -  Aug 11, 2014   
    P=N/A,  N=376, Completed, 
    Recruiting --> Completed | N=300 --> 376 | Trial primary completion date: Jun 2016 --> Jul 2012
  • ||||||||||  Orencia (abatacept) / BMS
    Enrollment change, Trial initiation date, Trial primary completion date:  Methotrexate-Inadequate Response Study (clinicaltrials.gov) -  Aug 8, 2014   
    P3,  N=1482, Completed, 
    Recruiting --> Completed | N=300 --> 376 | Trial primary completion date: Jun 2016 --> Jul 2012 N=62 --> 1482 | Initiation date: Nov 2009 --> Jan 2008 | Trial primary completion date: Feb 2010 --> Nov 2009
  • ||||||||||  amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
    Enrollment open:  A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303 (clinicaltrials.gov) -  Aug 8, 2014   
    P1,  N=0, Recruiting, 
    Initiation date: Mar 2014 --> Sep 2014 | Trial primary completion date: Mar 2016 --> Sep 2016 Not yet recruiting --> Recruiting
  • ||||||||||  baminercept (BG 9924) / Biogen
    Enrollment closed, Trial primary completion date:  Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sj (clinicaltrials.gov) -  Aug 8, 2014   
    P2,  N=72, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2014 --> Dec 2014
  • ||||||||||  Cyltezo (adalimumab biosimilar) / Boehringer Ingelheim
    Enrollment open, Trial primary completion date:  VOLTAIRE-RA: BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) -  Aug 7, 2014   
    P3,  N=600, Recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2014 --> Dec 2014 Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2015 --> Jan 2016
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Trial completion:  Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases (clinicaltrials.gov) -  Aug 6, 2014   
    P=N/A,  N=19, Completed, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Sep 2014 Recruiting --> Completed
  • ||||||||||  Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku
    Enrollment closed:  Long-Term Efficacy and Safety of CT-P10 in Patients With RA (clinicaltrials.gov) -  Aug 6, 2014   
    P1,  N=102, Active, not recruiting, 
    Recruiting --> Completed Enrolling by invitation --> Active, not recruiting
  • ||||||||||  Orencia (abatacept) / BMS
    P4 data, Trial primary completion date:  Korean Post-marketing Surveillance for Orencia® (clinicaltrials.gov) -  Aug 5, 2014   
    P=N/A,  N=600, Recruiting, 
    Recruiting --> Active, not recruiting | N=172 --> 215 Trial primary completion date: Mar 2016 --> Jul 2016
  • ||||||||||  Phase classification, Enrollment change, Trial termination, Trial primary completion date:  Long-term Clinical Effectiveness of the Delta Xtend Reverse Total Shoulder (clinicaltrials.gov) -  Aug 5, 2014   
    P=N/A,  N=144, Terminated, 
    Trial primary completion date: Mar 2016 --> Jul 2016 Phase classification: P4 --> P=N/A | N=250 --> 144 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2021 --> Jun 2014; Study was stopped due to low follow-up compliance at study sites.
  • ||||||||||  Enrollment closed, Trial primary completion date:  LARMES: Tear Analysis in the Diagnosis of Multiple Sclerosis (clinicaltrials.gov) -  Aug 5, 2014   
    P=N/A,  N=100, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2014 --> Mar 2016
  • ||||||||||  Enbrel (etanercept) / Pfizer, Amgen
    Enrollment closed:  Islet After Kidney Transplant for Type 1 Diabetes (clinicaltrials.gov) -  Aug 5, 2014   
    P1/2,  N=10, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
  • ||||||||||  Cervarix (recombinant human papillomavirus bivalent vaccine) / GSK, Japan Vaccine
    Trial completion, Enrollment change, Trial primary completion date:  Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination (clinicaltrials.gov) -  Aug 4, 2014   
    P=N/A,  N=1516, Completed, 
    Recruiting --> Completed | N=380 --> 28 | Trial primary completion date: Oct 2015 --> Apr 2014 Recruiting --> Completed | N=140000 --> 1516 | Trial primary completion date: Jun 2014 --> Sep 2013
  • ||||||||||  toreforant (JNJ-38518168) / J&J
    Trial termination, Trial primary completion date, Biopsy:  A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) -  Aug 1, 2014   
    P2,  N=25, Terminated, 
    Trial primary completion date: Jun 2014 --> May 2015 Recruiting --> Terminated | Trial primary completion date: Oct 2015 --> Jul 2014; The study was stopped due to lack of efficacy in a study conducted in a similar population,38518168ARA2002-NCT01679951.
  • ||||||||||  Tysabri (natalizumab) / Biogen, Royalty, Fumaderm (dimethyl fumarate) / Biogen
    Enrollment closed:  IIT6: Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design (clinicaltrials.gov) -  Aug 1, 2014   
    P=N/A,  N=30, Active, not recruiting, 
    Recruiting --> Terminated | Trial primary completion date: Oct 2015 --> Jul 2014; The study was stopped due to lack of efficacy in a study conducted in a similar population,38518168ARA2002-NCT01679951. Recruiting --> Active, not recruiting
  • ||||||||||  Enrollment closed:  A Clinical Investigation of the Discovery™ Elbow System (clinicaltrials.gov) -  Aug 1, 2014   
    P=N/A,  N=120, Active, not recruiting, 
    Recruiting --> Active, not recruiting Enrolling by invitation --> Active, not recruiting